Istradefylline is considered a nondopaminergic symptomatic anti‐PD pharmacotherapy,4, 5 with adenosine A2A receptor antagonism in the basal ganglia, but also a lack of influence on dopaminergic receptors/enzymes, and has demonstrated antiparkinsonian effects in clinical studies.6, 7. Here, ADORA2A is linked to Parkinson disease.